BRIEF-Antengene Announces IND Approval In China For Phase Ib/II Study Of ATG-022 In Combination With Keytruda

Reuters
Dec 02, 2025
BRIEF-Antengene Announces IND Approval In China For Phase Ib/II Study Of ATG-022 In Combination With Keytruda

Dec 2 (Reuters) - Antengene Corp Ltd 6996.HK:

  • ANTENGENE ANNOUNCES IND APPROVAL IN CHINA FOR PHASE IB/II STUDY OF ATG-022 (CLDN18.2 ADC) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) ± CHEMOTHERAPY

Source text: ID:nPn3vWhNGa

Further company coverage: 6996.HK

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10